Ryan M. Putney

Ryan M. Putney

Auto-generated profile, based on publicly available information

Ryan M. Putney

H. Lee Moffitt Cancer Center & Research Institute 5 , Tampa, Florida

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
AEAsmaa El-Kenawi
Asmaa El-Kenawi
ABAnders Berglund
Anders Berglund
VEVeronica Estrella
Veronica Estrella
YZYonghong Zhang
Yonghong Zhang
MLMin Liu
Min Liu
RGRobert Gatenby
Robert Gatenby
Induction of cell death represents a primary goal of most anticancer treatments. Despite the efficacy of such approaches, a small population of “persisters” develop evasion strategies to therapy-induced cell death. While previous studies have identified mechanisms of resistance to apoptosis, the mechanisms by which persisters dampen other forms of cell death, such as pyroptosis, remain to be elucidated. Pyroptosis is a form of inflammatory cell death that involves formation of membrane pores, ion gradient imbalance, water inflow, and membrane rupture. Herein, we investigate mechanisms by which cancer persisters resist pyroptosis, survive, then proliferate in the presence of tyrosine kinase inhibitors (TKI). Lung, prostate, and esophageal cancer persister cells remaining after treatments exhibited several hallmarks indicative of pyroptosis resistance. The inflammatory attributes of persisters included chronic activation of inflammasome, STING, and type I interferons. Comprehensive metabolomic characterization uncovered that TKI-induced pyroptotic persisters display high methionine consumption and excessive taurine production. Elevated methionine flux or exogenous taurine preserved plasma membrane integrity via osmolyte-mediated effects. Increased dependency on methionine flux decreased the level of one carbon metabolism intermediate S-(5′-adenosyl)-L-homocysteine, a determinant of cell methylation capacity. The consequent increase in methylation potential induced DNA hypermethylation of genes regulating metal ion balance and intrinsic immune response. This enabled thwarting TKI resistance by using the hypomethylating agent decitabine. In summary, the evolution of resistance to pyroptosis can occur via a stepwise process of physical acclimation and epigenetic changes without existing or recurrent mutations. Significance: Methionine enables cancer cells to persist by evading pyroptotic osmotic lysis, which leads to genome-wide hypermethylation that allows persisters to gain proliferative advantages.

29 January 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
BDBrittney L. Dickey
Brittney L. Dickey
RPRyan M. Putney
Ryan M. Putney
MSMichael Schell
Michael Schell
ABAnders Berglund
Anders Berglund
AAAntonio L. Amelio
Antonio L. Amelio
AGAnna R. Giuliano
Anna R. Giuliano
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. This study agnostically identified differentially methylated CpG sites to identify additional biomarkers to improve screening for early OPC. DNA was extracted from oral gargles of 89 early cases and 108 frequency matched healthy controls, and processed for genome-wide methylation using the Illumina Infinium MethylationEPIC BeadChip. Selected sites were combined with our prior methylation data in the EPB41L3 gene (CpG sites 438, 427, and 425) and oral HPV16 and HPV18 status were considered as binary variables (positive/negative). Lasso regression identified CpG sites strongly associated with early OPC. ROC curves with AUC were generated. The panel was validated utilizing bootstrap resampling. Machine learning analyses identified 14 markers that are significantly associated with early OPC, including one EPB41L3 CpG site (438) and oral HPV16 status. A final model was trained on all available samples using the discovered panel and was able to predict early OPC compared with controls with an AUC of 0.970 on the training set. In the bootstrap validation sets, the average AUC was 0.935, indicating adequate internal validity. Our data suggest that this panel can detect OPC early, however external validation of this panel is needed. Further refinement of a panel of biomarkers to diagnose OPC earlier is urgently needed to prevent complex treatment of OPC and associated comorbidities, while reducing risk of recurrence. Prevention Relevance: This study identified biomarkers using genome-wide methylation to create a panel capable of discerning early oropharyngeal cancer (OPC) from those without OPC. Such a biomarker panel would be an effective tool to detect OPC early and prevent complications of treatment associated with later diagnosis.

3 November 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
BHBoon Hao Hong
Boon Hao Hong
AOAdeniyi A. Olabumuyi
Adeniyi A. Olabumuyi
SZShuang G. Zhao
Shuang G. Zhao
PTPurvish Trivedi
Purvish Trivedi
RPRyan Putney
Ryan Putney
KYKosj Yamoah
Kosj Yamoah
Purpose: The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer, yet no direct comparison has been performed within the same patient cohort. Experimental Design: We sought to evaluate the concordance and prognostic value of GC and MMAI across multi-institutional cohorts totaling 688 patients with localized and oligometastatic prostate cancer. These included populations enriched for African American and East Asian patients. GC and MMAI scores were stratified into risk groups based on specimen type [biopsy or radical prostatectomy (RP)]. The primary endpoint was distant metastasis–free survival, measured from diagnosis to last follow-up or event. Results: GC and MMAI scores were significantly correlated across multiple cohorts. In Moffitt RP, biopsy, and National Cancer Centre Singapore cohorts, both MMAI and GC were prognostic alone and after adjusting for clinical variables. Multivariable analysis, including both biomarkers and clinical variables, showed that MMAI was significant even when accounting for GC in Moffitt RP and borderline in Moffitt biopsy. Analysis of concordant/discordant cases showed that patients who were high risk for both GC and MMAI did qualitatively worse. In pathway analysis, concordance with GC and MMAI was high for Moffitt RP and oligometastatic patients. Across both biopsy cohorts, although most biological pathways were concordant, there were consistent discordant signaling, metabolic, and DNA repair pathways. Conclusions: In the first direct patient-level comparison of GC and MMAI in prostate cancer, these biomarkers were found to demonstrate moderate correlation, and both biomarkers demonstrated prognostic value across diverse populations and disease states.


31 March 2023
Verified
Other
Open access
AEAsmaa El-Kenawi
Asmaa El-Kenawi
ABAnders Berglund
Anders Berglund
VEVeronica Estrella
Veronica Estrella
YZYonghong Zhang
Yonghong Zhang
MLMin Liu
Min Liu
RGRobert Gatenby
Robert Gatenby
Supplemental Materials Methods with additional references.

2 April 2024
Verified
Other
Open access
PDF file
BDBrittney L. Dickey
Brittney L. Dickey
RPRyan M. Putney
Ryan M. Putney
MSMichael Schell
Michael Schell
ABAnders Berglund
Anders Berglund
AAAntonio L. Amelio
Antonio L. Amelio
AGAnna R. Giuliano
Anna R. Giuliano
Supplemental Figure 1 shows the number of non-zero coefficients per variable that was examined in the variable selection processing for the final biomarker panel.